Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745224 · ClinicalTrials.gov registry record · NA
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
A NA study, sponsored by Cynosure.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT01745224 is a NA study that was terminated before completion, run by Cynosure. The registered enrollment target is 4 participants.
The verdict
NCT01745224, a NA study, was terminated before completion, sponsored by Cynosure.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
Interventions
- DEVICE Revlite Q switched Nd:YAG
- DEVICE Trivantage Q switched Nd: YAG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745224
The ClinicalTrials.gov registry entry for NCT01745224 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cynosure, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Revlite Q switched Nd:YAG is the first listed.
NCT01745224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01745224 about?
NCT01745224 is a clinical study titled "Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma". This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
What is the current status of trial NCT01745224?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01745224?
The interventions under investigation include: Revlite Q switched Nd:YAG (DEVICE), Trivantage Q switched Nd: YAG (DEVICE).
Who is sponsoring clinical trial NCT01745224?
This trial is sponsored by Cynosure, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.